ANTI-ENDOTHELIAL CELLS ANTIBODY MOUSE MONOCLONAL CLONE P1H12 PURIFIED FROM HYBRIDOMA CELL CULTURE

General description

Monoclonal Anti-Endothelial cells (CD146) (mouse IgG1 isotype) is derived from the P1H12 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from mice immunized with human umbilical cord cells (HUVEC). CD146 (cluster of differentiation 146) is also known as the melanoma cell adhesion molecule (MCAM), cell surface glycoprotein MUC18, A32, Mel-CAM and S-Endo-1. It is encoded by the MCAM gene. It belongs to the immunoglobulin supergene family with five immunoglobulin-like domains (V-V-C2-C2-C2), a transmembrane region and a 63 residue cytoplasmic tail. It is located on human chromosome11q23.

Specificity

Recognizes cultured microvascular and large-vessel endothelial cells (MVEC and HUVEC, respectively) and endothelial cells in tissues and in circulation.

Immunogen

human umbilical cord cells (HUVEC).

Application

Anti-Endothelial Cells antibody, Mouse monoclonal has been used in:

• immunocytochemistry
• immunohistochemistry
• flow cytometry
• immunoprecipitation
• enzyme-linked immunosorbent assay (ELISA)
• western blotting

Biochem/physiol Actions

CD146 (cluster of differentiation 146) expression can stimulate tumor development in human melanoma, through enhanced interaction between melanoma cells and endothelial cells. However, in breast carcinoma, CD146 may act as a tumor suppressor. CD146 is expressed by the intermediate trophoblast in the placental site and binds to its putative receptor in uterine smooth muscle cells during implantation and placentation, thus limiting trophoblastic invasion in the myometrium.

Soluble CD146 (cluster of differentiation 146) is associated with the activation of angiogenesis. Circulating endothelial cells (CECs) may help in predicting clinical outcome in cancer patients. Tumor endothelial markers are expressed in a wide range of tumor types and in normal vessels associated with wound healing and corpus luteum formation. It may have significant implications for the development of anti-angiogenic therapies as well.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.